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http://dx.doi.org/10.1016/j.ccr.2013.01.026SUMMARYImatinib eradicates dividing progenitor cells of chronic myeloid leukemia (CML) but does not effectively
target nondividing leukemia-initiating cells (LICs); thus, the disease often relapse after its discontinuation.
We now show that Fbxw7 plays a pivotal role in maintenance of quiescence in LICs of CML by reducing
the level of c-Myc. Abrogation of quiescence in LICs by Fbxw7 ablation increased their sensitivity to imatinib,
and the combination of Fbxw7 ablation with imatinib treatment resulted in a greater depletion of LICs than of
normal hematopoietic stem cells in mice. Purging of LICs by targeting Fbxw7 to interrupt their quiescence
and subsequent treatment with imatinib may thus provide the basis for a promising therapeutic approach
to CML.INTRODUCTION
Cancer-initiating cells (CICs) are thought to constitute a minor
subpopulation of cancer cells that is required for the initiation
and maintenance of cancer (Clevers, 2011; Huntly and Gilliland,
2005). This notion is based largely on the characterization of
leukemia-initiating cells (LICs), a rare subpopulation of cells
that propagates leukemia (Lapidot et al., 1994). LICs were
recently shown to share many properties, including self-renewal,
pluripotency, and quiescence, with normal hematopoietic stem
cells (HSCs) (Clevers, 2011; Huntly and Gilliland, 2005). A funda-
mental problem in treating leukemia is that the quiescent LIC
subpopulation is particularly resistant to conventional chemo-
therapy and radiation, both of which target cells undergoing
DNA replication and are therefore not effective against quiescentSignificance
Most cancer-initiating cells (CICs) are quiescent and therefo
dividing cells. CICs that survive therapy are a potential cause o
tain quiescence is thus critical for the elimination of cancer. Her
quiescence in leukemia-initiating cells (LICs) of chronic myeloid
results in deregulated activation of c-Myc and impaired mainte
and consequent cell exhaustion. Moreover, they provide a
currently available drugs by interrupting their quiescence, pot(noncycling) cells (Clevers, 2011; Huntly and Gilliland, 2005).
Failure to eradicate quiescent LICs may result in reinitiation of
malignancy after a period of latency. The development of thera-
peutic approaches that target quiescent CICsmight therefore be
expected to have a profound impact on cancer eradication.
Chronic myeloid leukemia (CML) in humans is characterized
by the presence of the Philadelphia chromosome, which is
generated by a chromosomal translocation that joins the BCR
gene on chromosome 22 to the ABL gene on chromosome 9
(de Klein et al., 1982; Rowley, 1973). CML is a biphasic myelo-
proliferative disorder, which initially assumes a chronic phase
before progressing to an accelerated phase and finally to blast
crisis. Given that individuals with CML in blast crisis have
a poor prognosis associated with a short survival time, it is crit-
ical to treat CML patients during the chronic phase. Several linesre resistant to anticancer drugs that preferentially target
f relapse. Elucidation of the mechanism by which CICsmain-
e, we show that Fbxw7 plays a pivotal role in maintenance of
leukemia. Our findings reveal that ablation of Fbxw7 in LICs
nance of quiescence followed by p53-dependent apoptosis
rationale for Fbxw7-targeted therapy to sensitize LICs to
entially resulting in a substantial survival benefit.
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Fbxw7 Loss Eliminates Leukemia-Initiating Cellsof evidence indicate that LICs of CML emerge as a result of
expression of BCR-ABL in normal HSCs (Pear et al., 1998), sup-
porting the notion that CML is a ‘‘stem cell disease.’’
The BCR-ABL fusion protein possesses constitutive tyrosine
kinase activity and triggers molecular events that result in the
expansion of malignant hematopoiesis (Deininger et al., 2000).
The recent development of the tyrosine kinase inhibitor (TKI) ima-
tinib represented abreakthrough in treatment of the chronic phase
of CML, resulting in a marked improvement in the prognosis
of CML patients (Druker et al., 2001; Kantarjian et al., 2002).
The French CML Intergroup Stop Imatinib study recently found
that 40% of CML patients in complete molecular remission
for >2 years while on treatment with imatinib did not relapsewithin
12 months after discontinuation of imatinib treatment (Mahon
et al., 2010). However, this observation suggests that LICs of
CML persist in more than half of patients treated with imatinib
alone, resulting in relapse after discontinuation of imatinib treat-
ment. Several mechanisms of resistance of CML LICs to imatinib
therapyhavebeensuggested, including themaintenanceofquies-
cence (Holtz et al., 2007) and the lack of addiction to BCR-ABL in
these cells (Corbin et al., 2011). Although more potent TKIs such
as nilotinib and dasatinib have been developed, these drugs
also do not target quiescent LICs of CML (Copland et al., 2006;
Jørgensen et al., 2007). Therapy with these TKIs thus serves to
suppress, not to eliminate, the disease. Moreover, quiescence in
CML LICs is thought not only to contribute to TKI resistance but
also to be essential for their long-term maintenance. Elucidation
of the molecular mechanism by which LICs maintain quiescence
is therefore expected to provide a basis for the development of
approaches tosensitizeCMLLICs toTKI therapy, therebyallowing
efficient eradication of leukemia cells, prevention of relapse, and
increased patient survival. Although several key molecules and
signaling pathways have been implicated in LIC maintenance (Ito
et al., 2008; Naka et al., 2010; Zhao et al., 2007), the mechanism
by which LICs maintain quiescence has been poorly understood.
c-Myc is one of the best characterized proteins found to deter-
mine the state of cell proliferation or quiescence (Laurenti et al.,
2009). Regulation of the abundance of c-Myc is achieved at
several levels, one of which is control of protein stability medi-
ated by posttranslational modification. We and others have
shown that the F-box protein Fbxw7 (also known as Fbw7,
Sel-10, hCdc4, or hAgo), the substrate-recognition subunit of
an SCF-type ubiquitin ligase complex, interacts with and medi-
ates the ubiquitylation of c-Myc (Nakayama and Nakayama,
2006). The ubiquitin-dependent degradation of c-Myc mediated
by Fbxw7 has been found to be essential for maintenance of the
quiescence and reconstitution capacity of normal HSCs (Mat-
suoka et al., 2008; Reavie et al., 2010; Thompson et al., 2008).
Given that LICs share many properties with normal HSCs, we
hypothesized that Fbxw7 might also be required for the mainte-
nance of LICs and that the Fbxw7–c-Myc axis might be a prom-
ising target for leukemia therapy.
RESULTS
Fbxw7 Is Required for Maintenance of Quiescence
in LICs
To examine whether Fbxw7 expression is modulated during
leukemogenesis, we first measured the amount of Fbxw7348 Cancer Cell 23, 347–361, March 18, 2013 ª2013 Elsevier Inc.mRNA at various stages of the differentiation of leukemic cells
in a mouse model of CML caused by the human BCR-ABL
fusion protein (Pear et al., 1998). For generation of the model,
a c-Kit+Sca-1+Lin (KSL) fraction of bone marrow cells, which
represents immature hematopoietic cells, was infected with
a retrovirus encoding both p210BCR-ABL and green fluorescent
protein (GFP) and was subsequently transplanted into syngeneic
recipients (Figure 1A). Recipient mice developed signs of CML,
including decreased activity, weight loss, an increased number
of myeloid cells in peripheral blood, and splenomegaly, and all
mice died within 4 weeks after transplantation. Bone marrow
cells were collected from the recipient mice after they began to
show such signs of CML. Reverse transcription (RT) and real-
time PCR analysis revealed that Fbxw7 mRNA was highly abun-
dant in the LIC compartment (GFP+KSL population), whereas
it was present in much smaller amounts in the leukemic
progenitor compartment (GFP+c-Kit+Sca-1Lin population)
and its abundance decreased further as cell differentiation pro-
gressed (Figure 1B). Similar results were obtained by quantifica-
tion of the copy number of Fbxw7mRNA per cell in these various
compartments (Figure S1A available online). These data thus
suggested that Fbxw7 expression during leukemogenesis is
regulated at least in part at the transcriptional level.
We next examined the role of Fbxw7 in themaintenance of LIC
quiescence by conditional disruption of the Fbxw7 gene in this
CML mouse model. KSL cells from Mx1-Cre;Fbxw7+/+ (control)
and Mx1-Cre;Fbxw7F/F mice were infected with the retrovirus
encoding BCR-ABL and GFP and were then transplanted into
syngeneic wild-type mice. The donor mice harbored wild-type
(+) or floxed (F) alleles of Fbxw7, as well as a transgene for Cre
recombinase under the control of the Mx1 gene promoter. The
number of white blood cells in peripheral blood of the recipient
mice was determined every 5 days; when it had increased
to >20,000/ml, GFP+KSL cells (2 3 104) were collected from
the recipients and transplanted into additional recipient mice
(first bone marrow transplantation [BMT]). These recipients
were then injected with polyinosinic:polycytidylic acid (pIpC)
beginning the day after the first BMT to activate the Mx1-Cre
transgene and thereby to delete the floxed Fbxw7 allele in
Mx1-Cre;Fbxw7F/F leukemia cells (to yield the Fbxw7D/D geno-
type) (Figure 1C). One week after the final injection of pIpC, we
confirmed that almost all floxed alleles of Fbxw7 were inacti-
vated in each fraction of the targeted leukemia cells (Figure S1B).
Analysis of the cell cycle status of leukemic cells from the recip-
ients of the first BMT by flow cytometry revealed that
the frequency of Hoechstlowpyronin Ylow cells, which represent
cells in G0 phase (quiescence), was significantly smaller in the
GFP+KSL compartment of Fbxw7D/D leukemia cells than in the
corresponding compartment of pIpC-treated Mx1-Cre;Fbxw7+/+
(control) leukemia cells (Figure 1D). Given that gene ablation
induced by pIpC is mediated by interferon, which has been
shown to act directly on HSCs to induce cell cycle progression
(Essers et al., 2009), recipients of control bone marrow cells as
well as those of Mx1-Cre;Fbxw7F/F cells were injected with
pIpC to eliminate any bias attributable to interferon action. In
contrast to LICs, most cells in the GFP+c-Kit+Sca-1Lin
compartment were actively cycling, and the proportion of quies-
cent cells in this compartment did not differ between the two
genotypes (Figure 1D), consistent with our observation that
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Figure 1. Loss of Fbxw7 in LICs Promotes Cell Cycle Progression
(A) Experimental strategy for generation of a mouse model of CML.
(B) GFP+ cells of control CML bone marrow were fractionated by FACS as indicated (left panels; PI, propidium iodide) and then assayed for Fbxw7 mRNA by RT
and real-time PCR analysis (right panel; n = 3).
(C) Experimental strategy for deletion of the floxed Fbxw7 allele in leukemic cells.
(D) CML bone marrow cells from recipients of the first BMT were subjected to flow cytometry (left panels) for determination of the percentage of quiescent cells in
the indicated fractions (right panel; n = 3).
Data are means ± SD. **p < 0.01; NS, not significant. See also Figure S1.
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Fbxw7 Loss Eliminates Leukemia-Initiating Cellsthese cells express Fbxw7 at a low level (Figure 1B). Together,
these results suggested that Fbxw7 is expressed predominantly
in the LIC fraction of leukemia cells and is required for mainte-
nance of quiescence in LICs.
Fbxw7 Is Required for Leukemic Stemness
The critical role of Fbxw7 in the maintenance of quiescence in
LICs and the fact that quiescence is thought to be essential for
maintenance of normal HSCs prompted us to examine whether
Fbxw7 is essential for LIC maintenance. To test this possibility,
we first performed long-term culture-initiating cell assays.
Control and Fbxw7D/D GFP+KSL cells were isolated from recipi-
ents of the first BMT, cultured on OP-9 stromal cells for 2 or
6 weeks, and then subjected to colony-formation assays (Fig-
ure 2A). In these assays, the number of colony-forming cells
arising after short-term culture (2 weeks) on OP-9 cells mainly
reflects progenitor function, whereas that arising after long-
term culture (6 weeks) reflects stem cell function (Matsumoto
et al., 2011b). We confirmed that the floxed alleles of Fbxw7
were indeed inactivated efficiently in the Fbxw7D/D leukemic cells
cultured on OP-9 cells (Figure S2A). The number of cells derived
from Fbxw7D/D GFP+KSL cells during culture on OP-9 cells wassmaller than that derived from the corresponding control cells
(Figure S2B). Furthermore, whereas the number of colonies
derived from the cells cultured for the short term (2 weeks) did
not differ between the two genotypes (Figure 2B), the number
of colonies formed by Fbxw7D/DGFP+KSL cells was significantly
smaller than that formed by the control cells after long-term
culture (6 weeks), suggesting that increased cycling of Fbxw7D/D
LICs eventually results in their exhaustion. We also performed
serial replating assays and confirmed that almost all floxed
alleles of Fbxw7 were inactivated in the targeted leukemic cells
after serial replating (Figure S2C). Whereas the number of colo-
nies formed did not differ between control and Fbxw7-deficient
LICs in the first plating, the number of colonies derived from
Fbxw7-deficient LICs was significantly smaller than that derived
from control LICs in the second plating (Figure S2D).
To assess the repopulating ability of Fbxw7D/D LICs in vivo, we
performed serial BMT experiments in which we collected control
and Fbxw7D/DGFP+KSL cells (23 104) from the recipients of the
first BMT and transplanted these cells into new recipients
(second BMT) (Figure 2C). Almost all floxed alleles of Fbxw7
were inactivated in the targeted leukemic cells isolated from
the recipients of the second BMT (Figure S2E). Whereas theCancer Cell 23, 347–361, March 18, 2013 ª2013 Elsevier Inc. 349
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Figure 2. Loss of Fbxw7 in LICs Results in Cell Exhaustion
(A) Experimental strategy for colony formation assays.
(B) Colony formation by BCR-ABL-transduced KSL cells of the indicated genotypes after 2 or 6 weeks of culture on OP-9 cells (n = 3).
(C) Experimental strategy for serial BMT experiments.
(D) Flow-cytometric determination of the absolute number of GFP+KSL cells in bone marrow of recipients (n = 5) after the first and second BMTs.
(E) Numbers of white blood cells (WBC) in peripheral blood of recipient mice (n = 10) after the first and second BMTs.
(F) Representative appearance (scale bar, 10 mm) and weight (n = 5) of the spleen in recipients of the second BMT.
(G) Survival of recipient mice (n = 10) after the first and second BMTs.
Data are means ± SD. **p < 0.01; NS, not significant. See also Figure S2.
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Fbxw7 Loss Eliminates Leukemia-Initiating Cellsnumber of GFP+KSL cells isolated from recipients of the first
BMT did not differ between the two genotypes, that of GFP+KSL
cells isolated from recipients of the second BMT was greatly
reduced in the case of Fbxw7D/D donor cells compared with
that for control donor cells (Figure 2D). These results thus sug-
gested that the loss of Fbxw7 results in disruption of quiescence,
followed by eventual exhaustion of LICs. We also observed that
both the proportion and absolute number of Fbxw7-deficient
leukemic progenitors were significantly smaller than those of
control leukemic progenitors in recipients of the second BMT
(Figures S2F and S2G). Given that Fbxw7 deficiency did not
affect the cell cycle status of the progenitors (Figure 1D), these
latter results were likely attributable to a functional defect in
Fbxw7-deficient LICs. Consistent with these observations, the
timing of CML development did not differ between the two types
of recipients of the first BMT (Figure 2E). In contrast, after the
second BMT, Fbxw7 deficiency prevented the propagation of
leukemic cells in peripheral blood (Figure 2E) and the spleen (Fig-
ure 2F). Furthermore, whereas most recipients of control LICs
died of CML at 30 days after the second BMT, 70% of mice
receiving Fbxw7D/D LICs survived for >120 days (Figure 2G;
data not shown). In a similar mouse model of CML, LICs were
also shown to give rise to acute lymphocytic leukemia (ALL)
with a long latency (Pear et al., 1998). Notably, we did not
observe development of ALL or CML in recipients of Fbxw7D/D
LICs later than 40 days after the second BMT. Flow cytometric
analysis and histological examination revealed the almost
complete absence of leukemic cells in peripheral blood and no
infiltration of leukemic cells in the spleen, liver, or lungs of the
recipients of Fbxw7-deficient LICs that survived for >90 days
after the second BMT (Figure S2H), suggesting that Fbxw7-defi-
cient LICs lose their potential to generate malignancies. Fbxw7
thus appears to be essential for the long-term maintenance of
leukemia-initiating potential.
Accumulation of c-Myc Is Responsible for Loss
of Leukemic Stemness
We next investigated the mechanism underlying LIC exhaustion
associated with Fbxw7 deficiency. Fbxw7 targets many
proteins related to HSC maintenance, including c-Myc, Notch1
intracellular domain (NICD1), and mammalian target of rapamy-
cin (mTOR) (Nakayama and Nakayama, 2006). To determine
whether these substrates accumulate in Fbxw7-deficient LICs,
we examined their abundance in LICs isolated from recipients
of the first BMT and found that the abundance of c-Myc was
increased in Fbxw7D/D GFP+KSL cells compared with control
GFP+KSL cells (Figure 3A). In contrast, the expression levels of
NICD1 and mTOR did not differ between control and Fbxw7-
deficient GFP+KSL cells (Figures S3A and S3B).
To determine whether c-Myc accumulation is responsible for
the phenotype of Fbxw7D/D LICs, we first cultured control and
Fbxw7D/D GFP+KSL cells isolated from recipients of the first
BMT with the c-Myc inhibitor 10058-F4 (Follis et al., 2009). A
colony-formation assay performed after culture of GFP+KSL
cells for 2 or 6 weeks in the presence of 10058-F4 revealed
that the number of colonies did not differ between the two geno-
types (Figure 3B). To confirm that 10058-F4 indeed inhibited
c-Myc function in these cells, we measured the abundance of
mRNAs for cyclin D2 and ornithine decarboxylase 1 (ODC1),the genes for which are direct targets of c-Myc. The abundance
of these mRNAs was increased in Fbxw7-deficient LICs
compared with that in control cells, and each increase was
attenuated by 10058-F4, suggesting that 10058-F4 indeed
inhibits c-Myc activity in these cells (Figure 3C). To demonstrate
further that c-Myc accumulation contributes to the phenotype
of Fbxw7-deficient LICs, we next generated Mx1-Cre;Fbxw7F/F;
c-Myc+/F mice in order to analyze the cell cycle status and
colony-forming ability of Fbxw7D/D;c-Myc+/D LICs. The loss of
quiescence and impaired colony-forming ability apparent for
Fbxw7-deficient LICs were normalized by the additional deletion
of one allele of the c-Myc gene (Figures 3D and 3E). In contrast,
neither a g-secretase inhibitor, N-[N-(3,5-difluorophenacetyl)-L-
alanyl]-S-phenylglycine t-butyl ester (DAPT), which antagonizes
Notch signaling, nor rapamycin, which antagonizes mTOR,
mimicked the effects of 10058-F4 or c-Myc depletion (Figures
S3C and S3D), suggesting that neither Notch nor mTOR contrib-
utes to the phenotype of Fbxw7-deficient LICs. Collectively,
these results thus indeed suggested that the phenotype of
Fbxw7D/D LICs is attributable to increased activity of c-Myc.
We next compared the amount of BCR-ABL between control
and Fbxw7-deficient LICs. Immunoblot analysis revealed no
substantial difference in the level of BCR-ABL between these
cells (Figure S3E). We further examined whether Fbxw7 defi-
ciency affects signaling downstream of BCR-ABL in LICs by
analyzing the phosphorylation of Stat5 (on Tyr694), Crkl (on
Tyr207), and Akt (on Ser473). Intracellular flow cytometric analysis
revealed that the proportions of cells expressing the phosphory-
lated forms of Stat5 or Crkl were similar for control and Fbxw7-
deficient LICs (Figures S3F and S3G). In contrast, the frequency
of cells positive for phosphorylated Akt was greater for Fbxw7-
deficient LICs than for control LICs (Figure S3H). We previously
showed that Akt phosphorylation is inhibited by transforming
growth factor–b (TGF-b) signaling in CML LICs (Naka et al.,
2010), and a recent study indicated that TGF-b is activated by
a niche for HSCs (Yamazaki et al., 2011). These observations
suggest that Fbxw7-deficient LICs might enter the cell cycle
and cease to interact with a LIC niche, resulting in a decrease
in TGF-b signaling and an increase in Akt phosphorylation.
Consistent with this notion, we found that the frequency of cells
positive for phosphorylated Smad2/3 was smaller for Fbxw7D/D
GFP+KSL cells than for control cells (Figure S3I). Moreover,
TGF-b1 treatment reversed the increase in the proportion of
Fbxw7-deficient LICs positive for phosphorylated Akt (Fig-
ure S3J), suggesting that downregulation of TGF-b signaling
indeed contributes to this increase. Collectively, our results
exclude the possibility that the phenotype of Fbxw7-deficient
LICs is attributable to downregulation of BCR-ABL itself or of
signaling downstream of BCR-ABL.
To further exclude the possibility that Fbxw7 deficiency in LICs
impairs their homing ability, we collected the same number of
control and Fbxw7D/D GFP+KSL cells from recipients of the first
BMT, transplanted the cells into new recipient mice, and deter-
mined the proportion of GFP+ cells among bone marrow cells
by flow cytometry at 12 hr after transplantation. We found that
the frequency of GFP+ cells did not differ significantly between
the two genotypes (Figure S3K), suggesting that the phenotype
of mice receiving Fbxw7-deficient LICs was not likely a conse-
quence of impaired homing.Cancer Cell 23, 347–361, March 18, 2013 ª2013 Elsevier Inc. 351
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Figure 3. Inhibition of c-Myc Rescues the Phenotype of Fbxw7-Deficient LICs
(A) The abundance of c-Myc in Fbxw7D/D or control GFP+KSL cells from mouse recipients of the first BMT was measured by flow cytometry (left panel). Relative
c-Myc immunofluorescence intensity (IFI) was determined (n = 5) (right panel). IgG, immunoglobulin G.
(B) Colony formation by Fbxw7D/D and control LICs after culture for 2 or 6 weeks with or without 10058-F4 (n = 5).
(C) Control and Fbxw7D/D LICs were assayed for cyclin D2 and ODC1 mRNAs by RT and real-time PCR analysis after culture on OP-9 cells for 2 weeks with or
without 10058-F4 (n = 5).
(D) The percentage of quiescent cells among GFP+KSL cells was determined for control, Fbxw7D/D, or Fbxw7D/D;c-Myc+/D bone marrow cells from recipients
(n = 5) of the first BMT.
(E) Colony formation by BCR-ABL-transduced KSL cells of the indicated genotypes after 2 or 6 weeks of culture on OP-9 cells (n = 3).
Data are means ± SD. **p < 0.01. See also Figure S3.
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Fbxw7 Loss Eliminates Leukemia-Initiating CellsLoss of Fbxw7 in LICs Induces Apoptosis
in a p53-Dependent Manner
Given that deregulation of c-Myc activation often triggers
apoptosis in a p53-dependent manner (Matsuoka et al., 2008;
Onoyama et al., 2007), we postulated that p53-dependent
apoptosis might be induced by accumulation of c-Myc in
Fbxw7-deficient LICs and contribute to LIC exhaustion. The
proportion of apoptotic cells did not differ significantly between
control and Fbxw7-deficient LICs isolated from recipients of the
first BMT. However, the frequency of annexin V+ apoptotic cells
was markedly greater among Fbxw7D/D GFP+KSL cells than
among control GFP+KSL cells from recipients of the second
BMT, whereas such a difference was not apparent for leukemic
progenitors (Figure 4A). To determine whether this apoptosis in
Fbxw7-deficient LICs is induced in a p53-dependent manner,
we next cultured control or Fbxw7D/D GFP+KSL cells isolated
from recipients of the first BMT with the p53 inhibitor pifithrin-a352 Cancer Cell 23, 347–361, March 18, 2013 ª2013 Elsevier Inc.(PFTa) (Komarov et al., 1999). Analysis of colony formation
revealed that the exhaustion apparent in Fbxw7D/D GFP+KSL
cells after 6 weeks of culture was efficiently inhibited by treat-
ment of the cells with PFTa (Figure 4B). To confirm that PFTa
indeed inhibits p53 function in these cells, we measured the
abundance of mRNAs for p21 and Noxa, the genes for which
are direct targets of p53. The amounts of these mRNAs were
increased in Fbxw7-deficient LICs compared with those in
control cells, and each increase was attenuated by treatment
with PFTa (Figure 4C), suggesting that PFTa indeed inhibits
p53 activity in these cells. To further show that Fbxw7 deficiency
in LICs induces apoptosis in a p53-dependent manner, we
generated Mx1-Cre;Fbxw7F/F;p53/mice in order to determine
the proportion of apoptotic cells and colony-forming ability
for Fbxw7D/D;p53/ LICs. The increase in the frequency of
apoptosis apparent for Fbxw7-deficient LICs from recipients of
the second BMT was not observed with Fbxw7D/D;p53/ LICs
AB C
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Figure 4. Apoptosis Is Induced in Fbxw7-Deficient LICs in a p53-Dependent Manner
(A) The frequency of annexin V+ cells among Fbxw7D/D and control cells of the indicated fractions from mouse recipients (n = 3) of the first or second BMT was
determined by flow cytometry. 7-AAD, 7-aminoactinomycin D.
(B) Colony formation by Fbxw7D/D and control LICs after culture for 2 or 6 weeks with or without PFTa (n = 5).
(C) Control and Fbxw7D/D LICs were assayed for p21 and Noxa mRNAs by RT and real-time PCR analysis after culture on OP-9 cells for 2 weeks with or without
PFTa (n = 5).
(D) The proportion of annexin V+ cells among GFP+KSL cells was determined by flow cytometry for control, Fbxw7D/D, or Fbxw7D/D;p53/ bone marrow cells
from recipients (n = 3) of the second BMT.
(E) Colony formation by cells of the indicated genotypes after culture for 2 or 6 weeks on OP-9 cells (n = 3).
Data are means ± SD. **p < 0.01; NS, not significant.
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Fbxw7 Loss Eliminates Leukemia-Initiating Cells(Figure 4D). Consistent with this finding, the decrease in the
number of colonies derived from Fbxw7-deficient LICs after
6 weeks of culture on OP-9 cells was reversed by deletion of
the p53 gene (Figure 4E). Collectively, these results indicated
that Fbxw7 deficiency in LICs results in deregulated c-Myc acti-
vation, impaired maintenance of quiescence, subsequent
apoptosis as a result of p53 induction, and consequent cell
exhaustion.
The Combination of Fbxw7 Ablation and Anticancer
Drug Treatment Is Effective for LIC Eradication
Although our results implicated Fbxw7 as a potential target for
leukemia therapy, the timing of CML development and the
survival rate did not differ between the recipients of the first
BMT harboring control or Fbxw7-deficient LICs (Figures 2E
and 2G), suggesting that inhibition of Fbxw7 alone would not
suffice as an effective therapy for CML. To address this problem,
we examined the effects of combining Fbxw7 ablation with ima-
tinib. Recipients of the first BMT were injected with pIpC on 7
alternate days beginning the day after transplantation and were
then administered imatinib twice a day at 100 mg/kg for 2 weeks
beginning 20 days after transplantation (Figure 5A). Determina-
tion of the proportion of annexin V+ cells among GFP+KSL
cells revealed that the frequency of apoptosis among imatinib-
treated Fbxw7D/D LICs was significantly greater than that
among imatinib-treated control LICs (Figure 5B), indicating that
Fbxw7-deficient LICs are sensitive to imatinib. In contrast, ima-
tinib was able to efficiently induce apoptosis in both control
and Fbxw7-deficient leukemic progenitors and bulk leukemic
cells. The number of colonies formed by imatinib-treated
Fbxw7D/D GFP+KSL cells was smaller than that formed by
vehicle-treated Fbxw7D/D GFP+KSL cells or by imatinib-treated
control GFP+KSL cells (Figure 5C).
Analysis of the effects of this combination therapy on CML
development in vivo revealed that it markedly reduced the
number of Fbxw7-deficient LICs (Figure 5D). Consistent with
these findings, most mice treated with imatinib alone showed
a moderate delay in the onset of disease but developed CML
after discontinuation of imatinib (Figure 5E), dying within
60 days after BMT (Figure 5F). In contrast, combination therapy
with Fbxw7 ablation and imatinib resulted in a marked attenua-
tion of CML development that remained apparent even after
discontinuation of imatinib treatment (Figures 5E and 5F).
Furthermore, when LICs isolated from recipients of the first
BMT were transplanted into new recipients, we found that,
whereas LICs treated with imatinib alone still had the potential
to confer disease, an apparently complete cure was achieved
in all recipients of LICs treated with the combination therapy of
Fbxw7 ablation and imatinib (Figure 5F). These results indicated
that the effectiveness of the combination therapy is attributable
to disrupted maintenance of LICs. We also combined Fbxw7
deletion and treatment with the conventional anticancer drug
cytosine arabinoside (Ara-C) and obtained similar results
(Figures S4A–S4D). Analysis of signaling downstream of BCR-
ABL in GFP+KSL cells isolated from recipients of the first BMT
at 36 days after transplantation revealed no differences in the
proportions of cells expressing phosphorylated forms of Stat5,
Crkl, or Akt between imatinib-treated control and Fbxw7D/D
LICs (Figures S4E–S4G). Collectively, these data thus suggested354 Cancer Cell 23, 347–361, March 18, 2013 ª2013 Elsevier Inc.that LICs whose quiescence is interrupted by Fbxw7 loss are
actively cycling and thus sensitive to imatinib or Ara-C treatment
and that these combination therapies of Fbxw7 ablation and
anticancer drug administration are able to eradicate LICs and
provide a survival advantage compared with currently available
treatments.
Fbxw7 Deficiency Affects LICs More than It Does
Normal HSCs
Given that Fbxw7 is essential for maintenance of both HSCs and
LICs, the targeting of LICs by Fbxw7 ablation combined with
anticancer drugs might also be expected to damage HSCs.
We thus compared the sensitivity of HSCs and LICs to Fbxw7
ablation. To this end, we infected KSL cells from control or
Mx1-Cre;Fbxw7F/F mice with the retrovirus encoding the
p210BCR-ABL oncoprotein and GFP (to yield LICs) or with a virus
encoding GFP alone (to yield HSCs) and then transplanted the
cells into recipient mice. GFP+KSL cells from these mice were
subsequently transferred to new recipients, which were then
injected with pIpC (Figure 6A). Analysis of GFP+KSL cells from
these latter recipients revealed that exit from quiescence
induced by Fbxw7 ablation was more pronounced for LICs
than for HSCs (Figure 6B). Accordingly, whereas the proportion
of apoptotic cells among LICs did not differ from that among
HSCs isolated from recipients of the first BMT, it was greater
for Fbxw7-deficient LICs than for Fbxw7-deficient HSCs isolated
from recipients of a second BMT (Figure 6C). Consistent with
these results, whereas Fbxw7 deficiency did not affect the
number of HSCs or LICs in recipients of the first BMT, it reduced
the number of LICs to a greater extent than it did that of HSCs in
recipients of the second BMT (Figure 6D).
To examine themechanism underlying this difference in sensi-
tivity to Fbxw7 deficiency between HSCs and LICs, we first
compared the amount of Fbxw7 mRNA in these cells. RT and
real-time PCR analysis revealed that the abundance of Fbxw7
mRNA in LICs was more than twice that in HSCs (Figure S5A).
Given that such an increase in the amount of Fbxw7 mRNA
was not observed in KSL cells expressing a kinase-dead
(K1176R) mutant of BCR-ABL (Zhang and Ren, 1998), the upre-
gulation of Fbxw7mRNA in LICs is likely attributable to BCR-ABL
kinase activity. The level of c-Myc mRNA was also markedly
increased in LICs compared with that in HSCs or in KSL cells
expressing the kinase-dead mutant of BCR-ABL (Figure S5B),
and intracellular flow cytometric analysis revealed that the abun-
dance of c-Myc in LICs was about five times that in HSCs or in
KSL cells expressing the BCR-ABL mutant (Figure S5C). We
also confirmed that these effects of BCR-ABL on KSL cells
were reversed by imatinib treatment (Figures S5A–S5C). We
further examined whether the difference in sensitivity to Fbxw7
deficiency between HSCs and LICs might be attributable to the
difference in the abundance of c-Myc in these cells. Both exit
from quiescence and apoptosis induced by Fbxw7 deletion
were more pronounced in HSCs overexpressing c-Myc and
were less pronounced in c-Myc+/D HSCs, than in control HSCs
(Figures S5D and S5E). Accordingly, the decrease in the number
of stem cells induced by Fbxw7 ablation in recipients of the
second BMT was greater for HSCs overexpressing c-Myc, and
smaller for c-Myc+/D HSCs, than for control HSCs (Figure S5F).
We next compared sensitivity to combination therapy with
AB
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Figure 5. Combination Therapy with Fbxw7 Ablation and Imatinib Eliminates LICs
(A) Experimental strategy for combination therapy with Fbxw7 ablation and imatinib administration.
(B) Frequency of annexin V positivity among Fbxw7D/D or control cells of the indicated fractions isolated from recipients (n = 3) of the first BMT after treatment with
imatinib or vehicle.
(C) Colony formation by Fbxw7D/D and control LICs cultured on OP-9 cells with imatinib or vehicle for 2 or 6 weeks (n = 3).
(D) Absolute number of GFP+KSL cells in bone marrow from mice (n = 5) treated as in (A).
(E) Frequency of GFP+ cells in peripheral blood from mice (n = 10) treated as in (A).
(F) Survival of recipients (n = 10) of the first and second BMT treated as in (A).
Data are means ± SD. **p < 0.01. See also Figure S4.
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Figure 6. Fbxw7 Deficiency Affects LICs to a Greater Extent than It Does Normal HSCs
(A) Experimental strategy to compare the sensitivity of LICs to Fbxw7 deficiency with that of normal HSCs.
(B) The relative percentage of quiescent cells among GFP+KSL cells for Fbxw7D/D cells comparedwith that for control cells infected with the corresponding vector
was determined for recipients of the first BMT (n = 5).
(C) The frequency of annexin V+ cells among GFP+KSL cells for Fbxw7D/D cells compared with that for control cells infected with the corresponding vector was
determined for recipients of the first and second BMTs (n = 3).
(legend continued on next page)
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LICs. The frequency of apoptosis among cells from recipient
mice treated with this combination therapywasmarkedly greater
for LICs than for HSCs (Figure 6E). Consistent with these results,
the decrease in the number of stem cells wasmore prominent for
LICs than for HSCs after combination therapy (Figure 6F).
Finally, to determine directly whether this combination therapy
is able to eradicate LICs while preserving normal HSC function,
we transplanted an equal number (13 104) of KSL cells infected
with a retrovirus encoding the fluorescent marker tdTomato (to
yield HSCs) and of KSL cells infected with the virus for BCR-
ABL and GFP (to yield LICs) into the same recipient mice and
then subjected the animals to combination therapy (Figure 6G).
Flow cytometric analysis revealed that this regimen reduced
the number of GFP+KSL cells (LICs) to a greater extent than it
did that of tdTomato+KSL cells (HSCs) (Figure S5G). We then
collected the same number (1 3 104) of tdTomato+KSL cells
and GFP+KSL cells from these recipients and again transplanted
them together into new recipients. Whereas Fbxw7-deficient
tdTomato+KSL cells (HSCs) persisted in these new recipients,
almost all Fbxw7-deficient GFP+KSL cells (LICs) were eradi-
cated (Figure 6H). Furthermore, whereas tdTomato+ cells
(normal progeny of HSCs) were detected in the peripheral blood,
virtually no GFP+ cells (leukemic progeny of LICs) were detected
(Figure 6I). Collectively, these observations thus reveal a differ-
ence in sensitivity to the combination therapy between HSCs
and LICs, referred to as a ‘‘therapeutic window,’’ and they thus
provide a rationale for further development of this potential
approach to the treatment of human leukemia.
Downregulation of Fbxw7 Is Effective for Eradication
of Human LICs
To examine whether Fbxw7 ablation is indeed effective for erad-
ication of human LICs in CML, we first measured the amount of
Fbxw7 mRNA at various stages of the differentiation of bone
marrow cells from patients in the chronic phase of CML. Similar
to our findings with the mouse model of CML (Figure 1B), Fbxw7
mRNAwas abundant in the LIC compartment (CD34+CD38Lin
fraction), and its amount decreased markedly as the cells
differentiated (Figure 7A). We next transfected bone marrow
cells from such patients with small interfering RNAs (siRNAs)
specific for Fbxw7 by electroporation, and we confirmed that
almost all LICs were successfully transfected without induction
of a substantial level of apoptosis by the procedure (Figure S6A)
and that Fbxw7 mRNA was depleted efficiently (Figure 7B).
Transfection with either of two independent such siRNAs re-
sulted in a decrease in the proportion of quiescent cells in the(D) The relative number of GFP+KSL cells among Fbxw7D/D cells compared with t
recipients of the first and second BMTs (n = 5).
(E) The proportion of apoptotic cells among GFP+KSL cells isolated from recipi
injected with pIpC and then treated with imatinib or vehicle for 14 days was dete
(F) The number of GFP+KSL cells in recipient mice processed as in (E) was dete
(G) Experimental strategy to examine directly the difference in sensitivity to com
(H) An equal number (13 104) of tdTomato+KSL cells and GFP+KSL cells was co
mice together with 2 3 105 bone marrow cells from wild-type mice (second B
recipients (n = 5) of the second BMT were determined.
(I) The frequencies of tdTomato+ cells and GFP+ cells in peripheral blood from th
Data are means ± SD. **p < 0.01; NS, not significant. See also Figure S5.LIC compartment (Figure 7C). Depletion of Fbxw7 in human
LICs resulted in marked enhancement of the induction of
apoptosis (Figure 7D) and the inhibition of colony formation (Fig-
ure 7E) by imatinib. Similar results were obtained with human
LICs subjected to combination therapy with Fbxw7 depletion
and Ara-C (Figures S6B and S6C).
Finally, we compared the sensitivity to Fbxw7 deficiency and
combination therapy between human HSCs and LICs. We first
measured the amount of Fbxw7 mRNA at various stages of the
differentiation of bone marrow cells from healthy volunteers
and found that Fbxw7 mRNA was abundant in HSCs and was
downregulated during cell differentiation (Figure S6D). Depletion
of Fbxw7 induced entry of human HSCs into the cell cycle (Fig-
ure S6E), and, as with mouse HSCs and LICs, this effect was
greater in LICs than in HSCs (Figure 7F). In addition, induction
of apoptosis and inhibition of colony formation by the combina-
tion of Fbxw7 depletion and imatinib treatment were more
pronounced in LICs than in HSCs (Figures 7G and 7H; Fig-
ure S6F). Together, these results suggested that the sensitivity
to combination therapy differs markedly between human HSCs
and LICs, as was the case with mouse HSCs and LICs and
that such therapy is a promising approach to the treatment of
human CML.
DISCUSSION
With the use of a mouse model of CML, we have found that
Fbxw7 has an indispensable role in maintenance of the quies-
cence as well as the stemness of LICs. Fbxw7-deficient LICs
became exhausted with time and incapable of generating CML
in transplanted animals. In contrast to LICs, leukemic progeni-
tors proliferated rapidly, and their cell cycle status was not
affected by Fbxw7 deficiency. The abundance of Fbxw7
mRNA was high in LICs and relatively low in leukemic progeni-
tors, suggesting that Fbxw7 expression is regulated at the tran-
scriptional level during leukemogenesis. The difference in cell
cycle status between LICs and leukemic progenitors is therefore
likely attributable, at least in part, to the difference in the abun-
dance of Fbxw7 in these cells. Although the mechanisms
responsible for regulation of Fbxw7 expression remain unknown,
given that the HSC niche is thought to maintain HSCs in a quies-
cent state, it is possible that signals from the LIC niche may
control Fbxw7 expression in LICs.
Our data also provide mechanistic insight into the mainte-
nance of LIC quiescence by Fbxw7. We found that c-Myc accu-
mulated in Fbxw7-deficient LICs, and either treatment with a
c-Myc inhibitor or deletion of one allele of the c-Myc genehat for control cells infected with the corresponding vector was determined for
ent mice harboring retrovirus-infected Mx1-Cre;Fbxw7F/F or control cells and
rmined (n = 3).
rmined relative to that in corresponding vehicle-treated recipients (n = 5).
bination therapy between LICs and normal HSCs.
llected from the recipients treated as in (G) and transplanted into new recipient
MT). The relative numbers of tdTomato+KSL cells and GFP+KSL cells in the
e recipients (n = 10) of the second BMT obtained as in (H) were determined.
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Figure 7. Combination Therapy with Fbxw7 Downregulation and Imatinib Is Effective for Eradication of Human LICs
(A) Bone marrow cells at various stages of differentiation from CML patients were fractionated by FACS and assayed for Fbxw7 mRNA by RT and real-time PCR
analysis (n = 3).
(B) Bone marrow cells from patients with CML were transfected with a control siRNA or one of two independent Fbxw7 siRNAs (KD#1 or KD#2), after which the
CD34+CD38Lin fraction was cultured on OP-9 cells for 3 days and then assayed for Fbxw7 mRNA (n = 3).
(C) Bonemarrow cells from CML patients were transfected with Fbxw7 siRNAs, after which the CD34+CD38Lin fraction was sorted and cultured on OP-9 cells
as in (B). The frequency of quiescent cells was then measured by flow cytometry (n = 3).
(D) Cells from CML patients were transfected, sorted, and cultured on OP-9 cells for 7 days. The cells were exposed (or not) to imatinib for the last 4 days of the
culture, after which the proportion of apoptotic cells was determined by staining with annexin V (n = 3).
(E) Colony formation by human CML LICs transfected with Fbxw7 siRNAs and treated with imatinib as in (D) (n = 3).
(F) The relative frequencies of quiescent cells among human HSCs and LICs transfected with Fbxw7 or control siRNAs were determined as in (C) (n = 3).
(G) The frequency of annexin V+ cells in human HSCs and LICs treated as in (D) (n = 3).
(H) The relative numbers of colonies formed by human HSCs and LICs transfected with Fbxw7 or control siRNAs and treated with vehicle or imatinib as in (D) were
determined (n = 3).
Data are means ± SD. *p < 0.05; **p < 0.01. NS, not significant. See also Figure S6.
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status and colony formation capacity. These results support the
notion that c-Myc activation is responsible for cell cycle progres-
sion and the resulting exhaustion of Fbxw7-deficient LICs.
Previous studies have indicated that an increase in metabolic
growth signaling alone, including activation of the mTOR
signaling pathway, is sufficient to drive quiescent HSCs into
the proliferative state (Yilmaz et al., 2006). Given that mTOR is
a candidate substrate of Fbxw7 (Mao et al., 2008), it was
possible that increased mTOR activity might be responsible for
the phenotype of Fbxw7-deficient LICs. However, we found
that mTOR did not accumulate in Fbxw7-deficient LICs, and
the mTOR signaling inhibitor rapamycin did not rescue the
phenotype of these cells. We therefore conclude that mTOR
activity is not related to the phenotype of Fbxw7-deficient LICs.
We also provide evidence that Fbxw7-deficient LICs are sensi-
tive to anticancer drugs and that combination therapy with
Fbxw7 ablation and such drugs is effective for LIC eradication,
resulting in a survival advantage over treatment with anticancer
drugs alone. Although the development of imatinib has substan-
tially improved the prognosis of CML patients (Druker et al.,
2001; Kantarjian et al., 2002), CML LICs are resistant to imatinib
and residual LICs give rise to relapse after discontinuation of
imatinib treatment (Mahon et al., 2010). Several mechanisms
underlying resistance to imatinib have been proposed, including
quiescence, BCR-ABL mutations such as T315I, and the lack
of addiction to BCR-ABL in LICs (Corbin et al., 2011; Gorre
et al., 2001; Holtz et al., 2007). Although more potent TKIs
such as nilotinib and dasatinib have been developed, these
drugs are also not able to overcome these mechanisms of TKI
resistance in LICs (Copland et al., 2006; Jørgensen et al.,
2007). We now show that combination therapy with Fbxw7 abla-
tion and imatinib markedly reduced the rate of relapse after
discontinuation of imatinib. We also obtained results suggesting
that such combination therapy is effective for eradication of LICs
in human CML.
Although our study suggests that inhibition of Fbxw7 might
represent a promising therapeutic approach for CML patients,
the application of Fbxw7 inhibition to the treatment of cancer
warrants careful consideration. Given that Fbxw7 has been
regarded as an oncosuppressor protein because it targets
many proto-oncoproteins, growth promoters, and antiapoptotic
molecules including cyclin E, c-Myc, Notch, c-Jun (Nakayama
and Nakayama, 2006), mTOR (Mao et al., 2008), and Mcl-1
(Inuzuka et al., 2011; Wertz et al., 2011), suppression of Fbxw7
might induce carcinogenesis or promote cancer growth. Never-
theless, our experimental evidence indicates that the combina-
tion therapy with Fbxw7 ablation and anticancer drugs is
effective for treatment of CML in a mouse model at the animal
level as well as for eradication of human LICs.
Another concern about Fbxw7-targeted therapy is whether
normal stem cells might be damaged. Fbxw7 also plays a pivotal
role in HSC maintenance (Matsuoka et al., 2008; Thompson
et al., 2008), and recent studies have shown that Fbxw7 is
a key regulator of the viability of neural stem and progenitor cells
(Hoeck et al., 2010; Matsumoto et al., 2011a). Although we found
that LICs are more sensitive to Fbxw7 deficiency than are HSCs,
suggesting that there is a therapeutic window in targeting Fbxw7
for therapy, it remains to be determined to what extent Fbxw7inhibition might damage stem cells in other tissues. To minimize
damage to normal stem cells, we propose that Fbxw7 inhibitors
should be used for only a limited period. Our present study
suggests that the difference in sensitivity to Fbxw7 inhibition
between LICs and HSCs is attributable at least in part to the
difference in the abundance of Fbxw7 or c-Myc in these cells
and that such therapy may be expandable to other types of
human cancer. Fbxw7 is therefore a promising target for the
discovery of anticancer drugs with a broad spectrum of activity
against many human cancers.
EXPERIMENTAL PROCEDURES
Mice
Generation of Fbxw7F/F mice was described previously (Onoyama et al., 2007).
They were crossed with Mx1-Cre transgenic mice (kindly provided by
K. Rajewsky) to generate Mx1-Cre;Fbxw7F/F mice, and Mx1-Cre;Fbxw7+/+
mice were used as controls. Fbxw7F/F mice were also crossed with c-MycF/F
mice (kindly provided by I.M. de Alboran) or p53–/– mice (Taconic). All
these mice were backcrossed with C57BL/6 mice for more than five genera-
tions. Expression of Cre recombinase in transplant recipients was induced
by intraperitoneal injection of pIpC (Merck) at a dose of 20 mg per kilogram
of body mass on 7 alternate days. C57BL/6 mice were obtained from The
Jackson Laboratory and were used as recipients. All mouse experiments
were approved by the Animal Ethics Committee of Kyushu University. For
some experiments, mice were injected intraperitoneally with Ara-C (Sigma)
at a dose of 150 mg/kg. Imatinib (Novartis) was administered by oral gavage
twice a day at a dose of 100 mg/kg.
Generation of CML Model
Immature c-Kit+Sca-1+Lin hematopoietic cells (KSL cells) were isolated by
fluorescence-activated cell sorting (FACS) from bone marrow of Mx1-
Cre;Fbxw7F/F and Mx1-Cre;Fbxw7+/+ mice and were cultured in serum-free
S-Clone SF-O3 medium (Sanko Junyaku) supplemented with mouse stem
cell factor (Wako) at 100 ng/ml as well as human thrombopoietin (PeproTech)
at 100 ng/ml. For generation of the CML mouse model, the KSL cells were
infected for 2 days with a retrovirus harboring the MSCV-BCR-ABL-IRES-
GFP construct (see Supplemental Experimental Procedures) with the use of
CombiMag (OZ Biosciences). GFP+ cells (2 3 104) were then isolated by
FACS and were injected intravenously into lethally irradiated (9.5 Gy)
C57BL/6 mice together with 2 3 105 bone marrow cells from C57BL/6 mice.
The efficiency of gene transduction as evaluated on the basis of GFP expres-
sion was 30 to 40% in all experiments. When the number of white blood cells
had increased to >20,000 /ml, we collected 2 3 104 GFP+KSL cells from the
recipient mice and transferred them to new recipients together with 2 3 105
bone marrow cells from C57BL/6 mice (first BMT). These new recipients
were injected with pIpC beginning the day after BMT as described earlier.
For serial transplantation, 1 3 104 or 2 3 104 GFP+KSL cells were collected
from recipient mice 3 weeks after the first BMT and were transplanted into
other recipient mice together with 2 3 105 bone marrow cells from C57BL/6
mice (second BMT).
Colony Formation Assays
Colony formation by mouse cells was examined with the use of Methocult
medium (MethoCult GF M3434, StemCell Technologies). Control and
Fbxw7D/D GFP+KSL cells (1 3 103) were collected from recipients of the first
BMT and then cultured under hypoxic (5% O2) conditions with OP-9 stromal
cells (Kodama et al., 1994) (RIKEN Cell Bank) for 2 or 6 weeks in six-well dishes
containing a–minimum essential medium (Sigma) supplemented with 12.5%
fetal bovine serum (Invitrogen), 12.5% horse serum (Invitrogen), and 1 nM
dexamethasone (Wako). The cells (2 3 104) were then collected and trans-
ferred to Methocult medium. Colonies were scored 1 week after plating for
determination of the number of colonies per 1000 GFP+KSL cells. For some
experiments, 100 mM 10058-F4 (Merck), 10 mMDAPT (Merck), 25 nM rapamy-
cin (Cell Signaling Technology), 10 mM PFTa (Merck), 100 nM Ara-C, or 5 mM
imatinib was added to the culture medium.Cancer Cell 23, 347–361, March 18, 2013 ª2013 Elsevier Inc. 359
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Viable bone marrow mononuclear cells from treatment-naive patients in the
chronic phase of CML and from healthy volunteers who had given informed
consent were obtained from AllCells. The use of these purchased samples
was considered exempt by the Ethics Committee of Kyushu University. To
examine the role of Fbxw7 in the maintenance of LICs for human CML and
normal HSCs, we transfected bone marrow mononuclear cells with 300 nM
Fbxw7 siRNAs (Stealth Select RNAi siRNA, Invitrogen) by electroporation
with the use of an Amaxa Nucleofector II device (Lonza) according to the
recommended protocol. The transfected cells were then stained with anti-
bodies to human CD34 (8G12), CD38 (HIT2), CD3 (SK7), CD16 (3G8), CD19
(SJ25C1), CD20 (L27), CD14 (MfP9), and CD56 (NCAM16.2) (BD Biosci-
ences). CD3, CD16, CD19, CD20, CD14, and CD56 were used as lineage
markers. CD34+CD38Lin cells (1 3 103) were purified by FACS and cocul-
tured with OP-9 cells for 7 days. For some experiments, 100 nM Ara-C or
5 mM imatinib was added to the cultures for Days 3 to 7. The human cells
were then assayed for apoptosis (see Supplemental Experimental Procedures)
or for colony formation; for the latter assay, the cells were transferred to
Methocult medium (MethoCult GF H4435, StemCell Technologies), and the
number of colonies was counted 1 week after plating.
Statistical Analysis
Quantitative data are presented as means ± SD and were analyzed by
Student’s t test, with the exception that survival curves were analyzed by
the log-rank nonparametric test. A p value of < 0.05 was considered statisti-
cally significant.
Other Experimental Procedures
Flow cytometry, preparation of recombinant retroviruses, cell cycle analysis,
detection of apoptosis, RT and real-time PCR analysis, and immunoblot anal-
ysis are described in Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found in this article online at http://dx.doi.org/10.1016/
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